Cinclus Pharma Q1 2026 Revenue Milestone Boosts Stock

Cinclus Pharma Q1 2026 earnings: first revenue of SEK 10 million, stock up 4.08%. New partnerships and financing boost confidence.

Today / 18:11|Last updated: Today / 18:14

Cinclus Pharma Q1 2026 Revenue Milestone Boosts Stock — Photo: Prepared by Bond.az

Cinclus Pharma reported its first-ever revenue in Q1 2026, reaching SEK 10 million. New partnerships in Europe and China drove this milestone.

The company's stock rose 4.08% pre-market, reflecting cautious investor optimism.

Strategic financing from Claret Capital Partners extends the runway through Q3 2027.

Focus remains on linaprazan glurate and the HEEALING 1 trial, with top-line results expected in Q4 2026.

More News

Grupo Multilaser Q1 2026 reports robust growth

Today / 16:50

541

Grupo Multilaser Q1 2026 reports robust growth

Grupo Multilaser reports strong Q1 2026 results with revenue and EPS growth, robust EBITDA, and positive cash flow. Strategic optimization and cost control drive performance.

TRANSCRIPTS →

Rubicon Organics Q1 2026 Earnings Miss, Stock Falls

Today / 16:40

576

Rubicon Organics Q1 2026 Earnings Miss, Stock Falls

Rubicon Organics Q1 2026 earnings miss: EPS of -0.04 CAD, revenue of 13.69 million CAD, stock down 11%. Company expects improvement in H2 2026.

TRANSCRIPTS →

Ser Educacional Q1 2026 Beats EPS, Misses Revenue

Today / 16:12

291

Ser Educacional Q1 2026 Beats EPS, Misses Revenue

Ser Educacional Q1 2026 beats EPS expectations but misses revenue targets. Stock falls 1.34% after-hours.

TRANSCRIPTS →

Vallourec Q1 2026 Beats Forecasts, Stock Fluctuates

Today / 14:40

852

Vallourec Q1 2026 Beats Forecasts, Stock Fluctuates

Vallourec Q1 2026 earnings beat forecasts; stock sees volatility. Strong EBITDA and cash flow highlight performance.

TRANSCRIPTS →

Home Depot Q1 2026 earnings beat forecasts, stock dips

Today / 14:20

889

Home Depot Q1 2026 earnings beat forecasts, stock dips

Home Depot Q1 2026 earnings beat forecasts with EPS of $3.43 and revenue of $41.8B. Stock dips 2.49% amid margin concerns.

TRANSCRIPTS →

Today / 14:03

352

Hera Group Q1 2026: Steady growth

Hera Group posts steady growth in Q1 2026 with net profit of EUR 155 million and EPS of $0.105.

TRANSCRIPTS →

Oxford Lane Capital NAV drops, stock dips

Today / 14:02

259

Oxford Lane Capital NAV drops, stock dips

Oxford Lane Capital Corp reports Q4 FY2026 results: NAV per share down, stock falls 4.03%. CLO yields decline. Read more on challenges and outlook.

TRANSCRIPTS →

Driven Brands Q4 2025 Revenue Growth Reported

Today / 13:43

246

Driven Brands Q4 2025 Revenue Growth Reported

Driven Brands Q4 2025 revenue grows 7.7% to $460.1M, EPS $0.34. Stock up 1.12%.

TRANSCRIPTS →

Today / 13:41

777

Ceragon Q1 2026 Revenue Beats Estimates

Ceragon Networks Q1 2026 revenue beat estimates at $85M. EPS $0.01. Stock rose 6.77% premarket. Full-year guidance reiterated.

TRANSCRIPTS →

Fractyl Health Q1 2026 EPS Beat, Shares Surge 23%

Today / 13:10

740

Fractyl Health Q1 2026 EPS Beat, Shares Surge 23%

Fractyl Health Q1 2026 EPS beat expectations by 76%, shares surged 23% after hours. Revita program data expected in Q4 2026.

TRANSCRIPTS →

Antalpha Q1 2026: EPS Misses Forecast, Stock Rises

Today / 13:01

272

Antalpha Q1 2026: EPS Misses Forecast, Stock Rises

Antalpha Q1 2026: EPS misses forecast at $0.07, stock rises 2.42%. Revenue up 52% to $20.7M. Web3 AI agent Nina launched. Q2 guidance $11M-$13M.

TRANSCRIPTS →

GNFC Q4 profit surges, stock climbs 5.17%

Today / 12:44

314

GNFC Q4 profit surges, stock climbs 5.17%

GNFC Q4 FY2026 strong results: revenue up 11%, PAT up 35%, stock rises 5.17%. Chemical segment drives growth.

TRANSCRIPTS →

...